Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor

Defective Differentiation of Myeloid and Plasmacytoid Dendritic Cells in Advanced Cancer Patients is not Normalized by Tyrosine Kinase Inhibition of the Vascular Endothelial Growth Factor Receptor

Saved in:

Bibliographic Details
Main Authors:	T. D. de Gruijl, G. Giaccone, R. J. Scheper, H. van Cruijsen, K. Hoekman, B. C. Kuenen, A. J. M. van den Eertwegh, A. G. M. Stam
Format:	Article
Language:	English
Published:	Wiley 2007-01-01
Series:	Clinical and Developmental Immunology
Online Access:	http://dx.doi.org/10.1155/2007/17315
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Plasmacytoid Dendritic Cells: From Heart to Vessels
by: Rosalinda Sorrentino, et al.
Published: (2010-01-01)

Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa
by: Rochelle Woudberg, et al.
Published: (2025-01-01)

Cerebrovascular stenosis related to tyrosine kinase inhibitor for chronic myeloid leukemia: two illustrative cases
by: Nozomi Sasaki, et al.
Published: (2025-01-01)

Characteristics of Plasmacytoid Dendritic Cell and CD4+ T Cell in HIV Elite Controllers
by: Jean-Philippe Herbeuval, et al.
Published: (2012-01-01)

Antigen Gene Transfer to Human Plasmacytoid Dendritic Cells Using Recombinant Adenovirus and Vaccinia Virus Vectors
by: Hetty J. Bontkes, et al.
Published: (2005-01-01)

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
by: Li Zhang, et al.
Published: (2023-01-01)

Promoting ER stress in a plasmacytoid dendritic cell line drives fibroblast activation
by: Beatriz H. Ferreira, et al.
Published: (2025-02-01)

A Rare Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Occurred in Postchemotherapy of Breast Cancer
by: Jiankun Tong, et al.
Published: (2023-01-01)

Metabolic deficiencies underlie reduced plasmacytoid dendritic cell IFN-I production following viral infection
by: Trever T. Greene, et al.
Published: (2025-02-01)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
by: Evan Pisick, et al.
Published: (2004-01-01)

Tyrosine Kinase Inhibitor-Induced Intracranial Artery Stenosis – A Rare Cause of TIA in a Patient of Chronic Myeloid Leukemia
by: Sumedh S Agrawal, et al.
Published: (2024-12-01)

TSG-6 Downregulates IFN-Alpha and TNF-Alpha Expression by Suppressing IRF7 Phosphorylation in Human Plasmacytoid Dendritic Cells
by: L. Kui, et al.
Published: (2017-01-01)

Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia
by: Melea A. Ward, et al.
Published: (2015-04-01)

Regulation of Endothelial Adherens Junctions by Tyrosine Phosphorylation
by: Alejandro Pablo Adam
Published: (2015-01-01)

USP8‐Dependent Family Tyrosine Kinase Promotes the Malignant Progression of Esophageal Squamous Cell Carcinoma by Upregulating Protein Tyrosine Kinase 2 Expression
by: Yuechang Wu, et al.
Published: (2025-01-01)

Role of Bruton's Tyrosine Kinase in B Cell Development
by: Alex Maas, et al.
Published: (2001-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01)

Spleen tyrosine kinase inhibitors disrupt human neutrophil swarming and antifungal functions
by: Alex Hopke, et al.
Published: (2025-01-01)

Protein tyrosine kinase but not protein kinase C inhibition blocks receptor induced alveolar macrophage activation
by: K. Pollock, et al.
Published: (1993-01-01)

Synergistic Stimulation with Different TLR7 Ligands Modulates Gene Expression Patterns in the Human Plasmacytoid Dendritic Cell Line CAL-1
by: Tobias Hilbert, et al.
Published: (2015-01-01)

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature
by: Ramona Meier-Lienhard, et al.
Published: (2025-01-01)

Baicalin and Baicalein Inhibit Src Tyrosine Kinase and Production of IL-6
by: Dubravko Jelić, et al.
Published: (2016-01-01)

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
by: Benjamin M. Heyman, et al.
Published: (2025-02-01)

Functional impairment of human myeloid dendritic cells during Schistosoma haematobium infection.
by: Bart Everts, et al.
Published: (2010-04-01)

Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis: A Neuromuscular Surprise
by: Hassam Ali, et al.
Published: (2021-01-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
by: Jihene Elloumi-Mseddi, et al.
Published: (2013-01-01)

Anti-microbial cetylpyridinium chloride suppresses mast cell function by targeting tyrosine phosphorylation of Syk kinase
by: Bright Obeng, et al.
Published: (2024-12-01)

Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [Tc] (AH-113018) or CY 5** (AH-112543) Labeled Peptide
by: Elaine M. Jagoda, et al.
Published: (2015-09-01)

Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on Behalf of the Polish Adult Leukemia Group
by: Ugo Giordano, et al.
Published: (2025-01-01)

Coronary Artery and Peripheral Vascular Disease in a Patient with Poorly Differentiated Thyroid Cancer Treated with the Tyrosine Kinase Inhibitor Lenvatinib
by: Vineeth Sukrithan, et al.
Published: (2023-01-01)

The Expression and Clinical Significance of Different Forms of Mer Receptor Tyrosine Kinase in Systemic Lupus Erythematosus
by: Huaqun Zhu, et al.
Published: (2014-01-01)

Pengaruh Likopen terhadap Kadar Soluble FMS-Like Tyrosine Kinase 1 pada Preeklamsi
by: Vaulinne Basyir, et al.
Published: (2021-02-01)

Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)
by: Maroun Bou Zerdan, et al.
Published: (2022-01-01)

The tyrosine kinase inhibitor lenvatinib is oxidized by rat cytochromes P450 and affects their expression in rat liver
by: Indra Radek, et al.
Published: (2024-09-01)

A review on the potential of Bruton’s tyrosine kinase (Btk) inhibitor – Ibrutinib for treatment of Multiple Myeloma (MM)
by: Sze-Ting Bong, et al.
Published: (2019-05-01)

Retraction: Bruton’s tyrosine kinase inhibition attenuates the cardiac dysfunction caused by cecal ligation and puncture in mice
by: Frontiers Editorial Office
Published: (2025-01-01)

Plasmacytoid Urothelial Carcinoma of the Bladder Metastatic to the Stomach: A Case Report
by: Philippe Nabbout, et al.
Published: (2012-01-01)

Cell-free expression and SMA copolymer encapsulation of a functional receptor tyrosine kinase disease variant, FGFR3-TACC3
by: Alexander J. D. Snow, et al.
Published: (2025-01-01)

Characterization of Interleukin-15-Transpresenting Dendritic Cells for Clinical Use
by: J. M. J. Van den Bergh, et al.
Published: (2017-01-01)

Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy
by: Shuai Wang, et al.
Published: (2025-02-01)